Innoviva (INVA) Amortization - Intangibles (2014 - 2026)
Innoviva posted quarterly Amortization - Intangibles of $6.6 million for Q1 2026, up 1.22% year-on-year from $6.5 million in Q1 2025, and down 0.97% on a QoQ basis from $6.6 million in Q3 2025.
Innoviva (INVA) has 6 years of Amortization - Intangibles data on file, last reported at $6.6 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization - Intangibles rose 1.22% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $26.1 million (up 1.4% YoY), and the FY2025 full-year result was $26.3 million, up 1.45% from the prior year.
- Amortization - Intangibles for Q1 2026 stood at $6.6 million, down from $6.6 million in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $6.6 million in Q3 2025 and bottomed at $1.5 million in Q3 2022.
- The 5-year median for Amortization - Intangibles is $6.5 million (2025), against an average of $5.7 million.
- The widest annual swing landed in 2023, when Amortization - Intangibles soared 330.18%; it then increased 0.17% in 2024.
- A 5-year view of Amortization - Intangibles shows it stood at $1.5 million in 2022, then jumped by 330.18% to $6.5 million in 2023, then grew by 0.17% to $6.5 million in 2024, then climbed by 1.64% to $6.6 million in 2025, then fell by 0.97% to $6.6 million in 2026.
- The last three Amortization - Intangibles figures came in at $6.6 million (Q1 2026), $6.6 million (Q3 2025), and $6.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.55 Mn |
| Sep 30, 2025 | 6.62 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 6.48 Mn |
| Sep 30, 2024 | 6.51 Mn |
| Jun 30, 2024 | 6.40 Mn |
| Mar 31, 2024 | 6.40 Mn |
| Sep 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 4.96 Mn |
| Mar 31, 2023 | 3.81 Mn |
| Sep 30, 2022 | 1.51 Mn |
| Sep 30, 2014 | 3.23 Mn |